Core Viewpoint - The Hong Kong stock market continues to adjust, but the innovative drug sector is experiencing a rally, with the Hong Kong Stock Connect Innovative Drug ETF (520880) rising for the fourth consecutive day, gaining over 2% and surpassing the 60-day moving average [1][3]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) opened high and rose by 2.02%, reaching a price of 0.555 [2]. - Major components of the ETF, such as InnoCare Pharma-B and Hutchison China MediTech, saw significant gains of over 6% and 4%, respectively [1][3]. Group 2: Regulatory Environment - The National Medical Products Administration (NMPA) has optimized the review and approval process for innovative drugs, encouraging the application of urgently needed foreign-origin original and generic drugs in China [1][3]. Group 3: Company Developments - Recent announcements from innovative drug companies include the acceptance of clinical trial applications for SAL0145 injection by Sinopharm and the approval of the innovative drug Rilapladib by Hengrui Medicine [3]. - Securities firms are increasingly optimistic about the innovative drug sector, with reports from Pacific Securities, Guotai Junan, and Industrial Securities recommending continued focus on the innovative drug and medical device industry chain [3]. Group 4: ETF Characteristics - The Hong Kong Stock Connect Innovative Drug ETF (520880) tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which has three unique advantages: it is purely focused on innovative drugs, has a high concentration of leading companies, and effectively controls risks associated with less liquid stocks [3][4]. - The top ten holdings in the ETF account for over 73% of its weight, highlighting the dominance of leading innovative drug companies [5].

Group 1 - The core viewpoint of the news highlights significant achievements in the innovation drug sector, with a record 76 innovative drugs expected to be approved for market in China by 2025, marking a historical high [1] - The healthcare payment system is continuously optimized, with the introduction of a "commercial insurance innovative drug directory" mechanism, which enhances the payment capacity for innovative drugs through the complementary combination of medical insurance and commercial insurance [1] - Institutions are optimistic about the pharmaceutical and biotechnology industry, with Donghai Securities predicting that China will officially enter a new era of innovative drugs by 2026 [1] Group 2 - The Hong Kong Stock Connect Innovative Drug ETF managed by Harvest (520970) tracks the CSI Hong Kong Stock Connect Innovative Drug Index, with the top ten weighted stocks including WuXi Biologics, Innovent Biologics, BeiGene, and others, accounting for over 71.80% of the total weight [2] - The management and custody fees for the Harvest Hong Kong Stock Connect Innovative Drug ETF are 0.60% per year, making it suitable for both ordinary investors as a long-term allocation tool and professional investors for flexible trading needs [2]

Group 1 - The Hong Kong stock market continues to adjust, but the innovative drug sector is experiencing gains, with the Hong Kong Stock Connect Innovative Drug ETF (520880) rising for the fourth consecutive day, up 2% and surpassing the 60-day moving average [1][8] - Major components of the ETF include companies like InnoCare Pharma-B, which rose over 6%, and Hutchison China MediTech, which increased by over 4% [1][8] - The National Medical Products Administration (NMPA) has optimized the review and approval process for innovative drugs, encouraging the application of urgently needed foreign-origin drugs and generics in China [1][10] Group 2 - Recent announcements from innovative drug companies include the acceptance of clinical trial applications for SAL0145 injection by Sinopharm and the approval of the innovative drug Ruilafup α injection by Hengrui Medicine [3][10] - Securities firms are increasingly optimistic about the innovative drug sector, with reports from Pacific Securities, Guotai Junan, and Industrial Securities recommending continued focus on the innovative drug and medical device industry chain [3][10] - The Hong Kong Stock Connect Innovative Drug ETF (520880) tracks the Hang Seng Stock Connect Innovative Drug Select Index, which has three unique advantages: it is purely focused on innovative drugs, has a high concentration of leading companies, and offers better risk control by reducing the weight of less liquid stocks [3][10] Group 3 - The top ten holdings in the Hong Kong Stock Connect Innovative Drug ETF account for over 73% of the total weight, indicating a strong presence of leading companies in the innovative drug sector [4][11] - Notable companies in the ETF include Kangfang Biologics (10.49% weight), BeiGene (10.01%), and CSPC Pharmaceutical Group (9.97%), among others, with a total market capitalization of approximately HKD 11.35 billion [4][11] - For investors looking to reduce volatility while still focusing on innovative drugs, the market offers the only pharmaceutical ETF (562050) that combines innovative drugs with traditional Chinese medicine, providing a more stable investment option [4][12]

Core Viewpoint - The Hong Kong stock market for innovative drugs has experienced a rally since the beginning of 2026, driven by positive clinical data from Arrowhead, which has boosted sentiment in the sector [1]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (159570) has shown strong performance, with a nearly 2% increase and a trading volume exceeding 9 billion, indicating high trading activity [6]. - As of January 7, 2026, the ETF's latest scale has surpassed 24.7 billion, leading its peers in the same category [6]. - The majority of the weighted stocks in the ETF index have shown positive performance, with notable increases from companies like Sanofi and Innovent Biologics [2]. Group 2: Company News - Strong Brain Technology, a brain-computer interface "unicorn," has completed a financing round of 2 billion, second only to Musk's Neuralink [1]. - Insilico Medicine, an AI-driven pharmaceutical company, has announced a long-term collaboration with Sihuan Pharmaceutical for anti-tumor drug development, with a total cooperation amount of 888 million [1]. Group 3: Industry Trends - The innovative drug industry is expected to continue its upward trend, with catalysts on the horizon. The market anticipates a busy period for business development (BD) transactions and data disclosures in early 2026 [4]. - The upcoming J.P. Morgan Healthcare Conference is expected to attract over 8,000 global participants, showcasing advancements in biotechnology, pharmaceuticals, and medical devices [5]. - Three major trends are emerging in the industry: the continued rise of gene and cell therapies, deep integration of AI in pharmaceuticals, and the rise of emerging market players [7]. Group 4: Investment Insights - The average total package for top multinational corporations (MNCs) purchasing innovative drugs or technology platforms from China in 2025 is 2.756 billion, indicating a willingness to pay higher prices for Chinese innovations [8]. - The focus of MNCs is shifting from merely acquiring products to obtaining platforms and time, emphasizing the importance of technology platforms that can produce new molecules [10]. - Investment logic suggests that MNCs are willing to pay premiums for clinically validated assets, particularly those that can fill pipeline gaps and provide immediate revenue [11].

Core Viewpoint - The pharmaceutical sector, particularly in innovative drugs, is experiencing a surge driven by significant clinical data in the small RNA weight loss field, leading to a notable increase in the STAR Market's innovative drug index and the corresponding ETF [1][3]. Group 1: Small RNA Weight Loss Data - Arrowhead Pharmaceuticals presented mid-stage data from its two small RNA weight loss projects, ARO-INHBE and ARO-ALK7, indicating a new paradigm in "high-quality weight loss" that focuses on visceral fat reduction rather than just weight loss [3][4]. - ARO-INHBE demonstrated a 9.4% weight loss in type 2 diabetes patients when combined with tirzepatide, significantly outperforming tirzepatide alone, which achieved a 4.8% reduction. Key metrics showed visceral fat reduction of 23.2%, total fat reduction of 15.4%, and liver fat reduction of 76.7%, approximately three times better than monotherapy [3][4]. - ARO-ALK7, the first RNAi therapy to validate fat cell gene knockdown effects in humans, achieved an average knockdown of 88% of ALK7 mRNA, with a maximum of 94%. After eight weeks of a single dose, visceral fat decreased by 14.1%, confirming the feasibility of targeting fat cell metabolic pathways [3][4]. Group 2: Significance of Visceral Fat Reduction - The ultimate goal of weight loss treatment is not merely the reduction of weight but the improvement of long-term cardiovascular, renal, and metabolic outcomes. Visceral fat, despite its low absolute quantity, is crucial as it surrounds vital organs and is linked to insulin resistance, fatty liver, and cardiovascular diseases [4]. - Effective reduction of visceral fat could significantly enhance metabolic status and lower the risk of long-term cardiovascular and renal events, providing higher clinical value for managing diabetes, obesity, and related complications [4]. Group 3: Synergy of Small RNA and GLP-1 - Current GLP-1 drugs are foundational in weight loss treatment but have unmet needs regarding visceral fat improvement, muscle loss, and rebound weight gain. The data suggests that small RNA drugs could complement fat metabolism pathways, enhancing the quality of weight loss rather than just the quantity [5]. - This validation of the synergistic logic between small RNA and GLP-1 strengthens market perception of the long-term value of the small RNA technology platform, leading to increased investment in high-research, innovative assets within the STAR Market [5]. Group 4: Future Outlook - The year 2026 is anticipated to be pivotal for small RNA drugs, with significant growth and validation expected, including commercial progress for Plozasiran and larger sample data readouts for ARO-INHBE and ARO-ALK7 [6]. - The capital market may see small RNA companies listing on the Hong Kong stock exchange, further enhancing market focus on this niche sector as overseas RNAi technology matures and domestic pipelines advance [6]. Group 5: Investment Opportunities - Following a period of adjustment, the innovative drug sector's overall valuation has returned to historically low levels. With the upcoming release of high-quality data and international conference catalysts, funds may begin reallocating towards high-elasticity sectors with medium to long-term industrial logic [7]. - Investors are encouraged to monitor developments in high-quality clinical data and international business development progress, which could drive further capital back into the innovative drug sector, potentially leading to a phase of upward trends [8].

Market Overview - The A-share market opened lower with the Shanghai Composite Index down 0.20%, the Shenzhen Component down 0.42%, and the ChiNext Index down 0.63% [2][3] - Over 3,000 stocks declined in the market, with sectors such as brokerage, insurance, retail, and CPO experiencing significant drops [1] Sector Performance - The electronic gas sector saw a strong opening, with Sanfu Co. and Heyuan Gas hitting the daily limit up, while Jin Hong Gas, Huate Gas, Silane Technology, and Yake Technology also showed notable gains [1] - The brain-computer interface concept remained active, with companies like Prit and Innovation Medical achieving four consecutive trading limit ups [1] Notable Stocks - Zhongke Lanyun opened over 12% higher, projecting a net profit increase of 367%-377% year-on-year for 2025 [3] - Yijing Optoelectronics approached the daily limit down, announcing an expected negative net profit for the year 2025 [5] Hong Kong Market - The Hong Kong stock market opened lower, with the Hang Seng Index down 0.59% and the Hang Seng Tech Index down 0.44% [5][6] - Major stocks such as Tencent Music, Baidu Group, Alibaba, and Zijin Mining experienced significant declines, while China Shenhua, China Telecom, and China Merchants Bank showed strength [5]

Core Viewpoint - Pharmaceutical stocks have risen significantly, driven by regulatory changes aimed at expediting the approval of urgently needed foreign drugs in China [1] Group 1: Stock Performance - Companies such as 加科思-B (01167) increased by 8.71% to HKD 7.24, 和铂医药-B (02142) rose by 7.61% to HKD 14.28, 复宏汉霖 (02696) gained 5.25% to HKD 67.2, and 映恩生物-B (09606) climbed 4.88% to HKD 365.6 [1] Group 2: Regulatory Changes - The National Medical Products Administration (NMPA) has optimized the review and approval process for urgently needed foreign drugs that are already on the market, aiming to meet the clinical needs of patients [1] - The NMPA emphasizes a clinical value-oriented approach, encouraging applicants to conduct global synchronous research and simultaneous submissions in China [1] - Original and generic drugs that are urgently needed and meet the criteria can be included in the priority review and approval category [1] Group 3: Market Outlook - Huatai Securities believes that the valuation of innovative drugs in the Hong Kong market remains attractive compared to global peers, attributing the liquidity discount to the decline in innovative drugs during November and December [1] - The firm anticipates that the ongoing liquidity recovery, along with continued business development (BD) activities and the upcoming JPM conference and annual report season, will boost the innovative drug sector [1] - The upward trend in the innovative drug sector is expected to continue as liquidity improves at the beginning of the year [1]

Market Overview - The Hong Kong stock market opened lower on January 8, with the Hang Seng Index down 0.59% at 26,302.78 points, the Hang Seng Tech Index down 0.44% at 5,713.53 points, the National Enterprises Index down 0.43% at 9,099.63 points, and the Red Chip Index down 0.14% at 4,109.34 points [1] - Major tech stocks mostly declined, with Alibaba down 1.58%, Tencent down 0.96%, JD.com down 0.79%, Xiaomi down 0.42%, Meituan down 0.77%, and Bilibili down 0.47% [1] - New stocks listed today included Zhihui, which rose over 3%, Tianshu Zhixin, which surged over 31%, and Jingfeng Medical-B, which increased over 36% [1] Company News - Xinyi International (00732.HK) reported a cumulative net operating revenue of approximately HKD 16.534 billion for 2025, a year-on-year decrease of about 7.3% [2] - China Overseas Development (00688.HK) announced a cumulative contract property sales amount of approximately RMB 251.231 billion for 2025, down 19.1% year-on-year [2] - Greentown China (03900.HK) reported a total contract sales amount of approximately RMB 251.9 billion for 2025, a decrease of 9% year-on-year [2] - China Overseas Hongyang Group (00081.HK) achieved a contract sales amount of RMB 2.57 billion for December 2025, down 43.9% year-on-year [3] - Qinhuangdao Port Co., Ltd. (03369.HK) reported a total throughput of 433 million tons for the year ending December 31, 2025, an increase of 4.48% year-on-year [4] - Lijun Pharmaceutical (01513.HK) announced that the injection of Laconchita monoclonal antibody has been included in the priority review and approval process [5] - Kinko Service (09666.HK) received acceptance from independent shareholders for 218.6 million shares without interests [6] - CICC (03908.HK) plans to issue no more than HKD 3 billion in perpetual subordinated bonds [7] - Agricultural Bank of China (01288.HK) saw Ping An Life increase its stake in its H-shares [8] - Aoyou Group (03383.HK) reported a total pre-sale amount of approximately RMB 8.57 billion as of December 31, 2025 [9] - CIMC Group (02039.HK) stated that the sale of property projects will reduce the group's net profit attributable to shareholders by approximately RMB 1.08 billion for 2025 [10] Stock Buybacks - Xiaomi Group-W (01810.HK) repurchased 3.9 million shares for HKD 149 million at prices between HKD 38.12 and HKD 38.2 [11] - Tencent Holdings (00700.HK) repurchased 1.023 million shares for HKD 636 million at prices between HKD 615.5 and HKD 628 [11] - Geely Automobile (00175.HK) repurchased 3.388 million shares for HKD 59.156 million at prices between HKD 17.38 and HKD 17.65 [12] Institutional Insights - Zheshang International noted that the fundamentals of the Hong Kong stock market remain weak, with a decline in the funding environment, while policy focus is on new productivity and expanding domestic demand [14] - Goldman Sachs maintains an "overweight" rating on Chinese A-shares and H-shares, citing attractive risk-reward ratios amid low profit growth and valuation levels [14] - FSMOne indicated that the valuation recovery of the Hang Seng Index has largely been achieved, with future performance dependent on corporate profit recovery [15] - Huatai Securities highlighted three investment opportunities under new industrialization: high-end manufacturing going global, strengthening domestic supply chains, and forward-looking investments in emerging industries [15]

Group 1 - The Hong Kong innovation drug sector has recorded a three-day consecutive rise since the beginning of 2026, with a rebound of approximately 10% in the main innovation drug index [1][8] - The Hong Kong Innovation Drug ETF (520880) has accumulated a gain of 9.24% since the start of the year, with a notable increase of over 3.4% on January 7 [1][8] - In 2025, the innovation drug sector represented by Hong Kong stocks saw an overall increase of over 60%, becoming a significant player in the market [3][11] Group 2 - The surge in the innovation drug sector at the beginning of 2025 is attributed to multiple catalysts, including favorable policies, better-than-expected industry data, and the approach of important industry conferences [5][13] - Significant developments include the approval of the first domestically produced CTLA-4 inhibitor "Daboshu" by Innovent Biologics and the approval of TROP2 ADC "Dercutuzumab" for breast cancer by AstraZeneca and Daiichi Sankyo, enhancing the ADC sector's competitive edge [5][13] - The total amount of outbound licensing for Chinese innovative drugs reached $135.655 billion in 2025, with 157 transactions, both setting historical records [5][13] Group 3 - The sector's valuation is currently at a relatively low level following previous adjustments, and there has been a noticeable inflow of funds driven by strong fundamental data [6][14] - Investment outlook for 2026 focuses on innovation and international expansion, with an emphasis on companies that have achieved significant business development (BD) transactions and those with unexpected overseas clinical progress [6][14] - The industry is entering a "dual-driven" 3.0 era of product development and commercial sales, with a clear upward trend in demand for next-generation therapies such as ADCs and dual antibodies [6][14] Group 4 - New technologies such as AI in drug development and brain-computer interfaces are expected to accelerate industrialization due to supportive policies and pricing [7][15] - Areas facing potential recovery include medical device exports, consumer healthcare, and OTC traditional Chinese medicine, which may present wave-like investment opportunities under improving policies or macroeconomic conditions [7][15] - The investment logic in the pharmaceutical sector for 2026 has shifted from broad-based gains to selective alpha strategies, favoring companies with robust technology and clear commercialization paths [7][15]

Core Viewpoint - The National Medical Products Administration (NMPA) is optimizing the review and approval process for urgently needed foreign drugs already on the market to meet the pressing clinical needs of patients in China [1][2]. Group 1: Regulatory Changes - The NMPA will enhance the review mechanism and accelerate the review speed while improving the inspection system to reflect the characteristics of various drug types [2]. - The NMPA encourages applicants to conduct global synchronous research and simultaneous application for market approval in China for urgently needed foreign drugs [1]. Group 2: Market Performance - In 2025, China approved a record 76 innovative drugs, significantly surpassing the 48 approved in 2024 [2]. - The total amount of authorized transactions for innovative drugs in 2025 exceeded $130 billion, with over 150 transactions, marking another historical high [2]. Group 3: Drug Composition - The 76 innovative drugs approved in 2025 include 47 chemical drugs, 23 biological products, and 6 traditional Chinese medicines [2]. - Among the 47 chemical drugs, 38 are domestic innovations, and 9 are imported, with domestic innovations accounting for 80.85% [2]. - For the 23 biological products, 21 are domestic innovations, and 2 are imported, with domestic innovations making up 91.30% [2]. Group 4: Industry Outlook - The release of the first version of the "Commercial Health Insurance Innovative Drug Directory" in December 2025 establishes a multi-layered payment system, creating new market pathways for high-value innovative drugs [2]. - Industry insiders are optimistic about 2026, anticipating a surge in innovative drug business development (BD) due to supportive industrial policies for true and high-level innovations [2]. - The dual push from commercial insurance implementation and procurement optimization is expected to sustain high prosperity in the innovative drug industry, with high-value innovative drugs likely to experience a second growth curve [2]. Group 5: Key Companies - Notable companies in the Hong Kong innovative drug sector include: Heng Rui Medicine, Kelun-Botai Biological, and others [3]. - Leading companies in the CXO sector include: Kailai Ying, Kanglong Chemical, and others [4].